Jacobs Levy Equity Management Inc. Sells 232,865 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Jacobs Levy Equity Management Inc. lessened its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 82.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,613 shares of the company's stock after selling 232,865 shares during the quarter. Jacobs Levy Equity Management Inc.'s holdings in Organogenesis were worth $156,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Organogenesis during the 4th quarter worth about $38,000. Palumbo Wealth Management LLC bought a new position in shares of Organogenesis during the fourth quarter worth about $65,000. Algert Global LLC bought a new position in shares of Organogenesis during the fourth quarter worth about $69,000. PDT Partners LLC acquired a new position in shares of Organogenesis in the fourth quarter worth approximately $110,000. Finally, Aquatic Capital Management LLC bought a new stake in Organogenesis in the fourth quarter valued at approximately $111,000. Institutional investors own 49.57% of the company's stock.

Insiders Place Their Bets

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the transaction, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. This represents a 13.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 36.90% of the stock is currently owned by corporate insiders.

Organogenesis Trading Down 2.4%

ORGO stock traded down $0.07 during midday trading on Friday, hitting $2.90. The stock had a trading volume of 609,283 shares, compared to its average volume of 1,175,760. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a market cap of $367.88 million, a P/E ratio of -48.33 and a beta of 1.85. The business has a fifty day moving average price of $4.21 and a two-hundred day moving average price of $3.91. Organogenesis Holdings Inc. has a 1-year low of $2.28 and a 1-year high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. On average, sell-side analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.